Adaptive Biotechnologies

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Adaptive Biotechnologies reports robust Q4 performance and eyes growth opportunities

Adaptive Biotechnologies delivered strong financial performance in Q4 2022 and full-year 2022, driven by growth in MRD and immune medicine segments, showcasing operational efficiency and revenue expansion.
While facing challenges such as paused T-Detect commercialization and revenue phasing complexities, the company is well-positioned to capitalize on opportunities like market acceptance of MRD and drug discovery partnerships.
With a positive revenue outlook for 2023, supported by strategic initiatives and a strong cash position, Adaptive Biotechnologies is poised for continued growth and market leadership in the biotechnology sector.

Adaptive Biotechnologies reports robust Q1 revenue and growth prospects

Adaptive Biotechnologies showcased strong revenue growth and operational improvements in Q1 2023.
The company is strategically positioned to capitalize on opportunities in MRD business and immune medicine segment.
Challenges include potential impacts from regulatory changes and the need for milestone achievements.
Overall, Adaptive Biotechnologies remains focused on growth, innovation, and expanding its market presence.

Adaptive Biotechnologies reports revenue growth and strategic partnerships in Q2

Adaptive Biotechnologies demonstrated solid revenue growth and margin improvement in Q2 2023, with a strategic outlook for future profitability.
Strong partnerships with Genentech and advocacy for MRD as a clinical endpoint position the company for continued success in the market.
Ongoing challenges in pricing and integration efforts are being addressed, while opportunities in drug discovery and AI-driven target discovery offer growth potential.

Adaptive Biotechnologies reports Q3 revenue growth amidst industry challenges

Adaptive Biotechnologies saw mixed performance with MRD growth and Immune Medicine decline.
Company's focus on MRD profitability and novel target identification shows strategic strength.
Facing challenges from industry softening and cost pressures but eyeing revenue growth opportunities.
Maintaining long-term target of $1,600 in 2027 while making progress towards profitability.

Adaptive Biotechnologies reports mixed Q4 results, focuses on MRD growth

Adaptive Biotechnologies navigated a transformative year in 2023, with a strong focus on MRD and Immune Medicine businesses. The company faces challenges in Immune Medicine revenue decline and achieving profitability. Strategic initiatives and partnerships position the company for growth and innovation in the biotechnology sector.

Adaptive Biotechnologies posts solid Q1 results, eyes breakeven targets

Adaptive Biotechnologies reported strong MRD revenue growth and aims to reduce operating expenses significantly in 2024. Despite a net loss, the company updated full-year guidance with a focus on achieving breakeven targets by 2025 and 2026. Opportunities lie in MRD segment expansion and immune medicine development.

Adaptive Biotechnologies excels in Q3 2024, eyes growth opportunities

Adaptive Biotechnologies delivered a robust performance in Q3 2024, marked by revenue growth, cost efficiencies, and strategic advancements in key segments.
While facing challenges in maintaining growth and profitability, the company's focus on operational excellence and innovation positions it well for future success.
With upcoming product launches and continued R&D efforts, Adaptive Biotechnologies is poised to capitalize on opportunities for market expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Paragon 28

Newamsterdam Pharma Co NV

As of Dec. 11, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Collapse This Quarter

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in more than 65 abstracts across eight different types of blood cancer at the 66th Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2024, in San Diego. Among these abstracts are a plenary session presentation, a late-breaking abstract and 25 other oral presentations.

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?

Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, driven by clonoSEQ, continues to show significant growth, and the company's balance sheet remains strong. An updated analysis around Adaptive Biotechnologies follows in the paragraphs below.

Adaptive Biotechnologies: Making Some Progress

The consensus price target hints at a 31.4% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head of IR Chad Robins - CEO and Co-Founder Kyle Piskel - CFO Susan Bobulsky - Chief Commercial Officer Conference Call Participants Dan Brennan - TD Cowen Mark Massaro - BTIG Matt Sykes - Goldman Sachs Maggie Boeye - William Blair Corey Rosenbaum - Scotiabank Operator Good day, and welcome to Adaptive Biotechnologies Third Quarter Financial Results [Operator Instructions]. As a reminder, this call may be recorded.

Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.35 per share a year ago.

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates

clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Diagnostics Services Program (MolDX), has expanded coverage of clonoSEQ® to include detection and monitoring of measurable residual disease (MRD) in Medicare patients with mantle cell lymphoma (MCL). MCL is a sub-type of non-Hodgkin lymphoma (NHL) with an annual incidence of approximately 4,000 cases per year in the United States.1 It is an aggressive disease, and most patients will relapse repeatedly; some shortly after frontline therapy, while others as late as 15 years after initial remission.2 , 3 Given this challenging and variable course of disease, it is critical to effectively assess depth of response in patients undergoing treatment and monitor for recurrence or disease progression following remission.

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

SEATTLE, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY.

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Karina Calzadilla – Head-Investor Relations Chad Robins – Chief Executive Officer and Co-Founder Kyle Piskel – Chief Financial Officer Susan Bobulsky – Chief Commercial Officer-MRD Conference Call Participants Mark Massaro – BTIG David Westenberg – Piper Sandler Tejas Savant – Morgan Stanley Dan Brennan – TD Cowen Andrew Brackmann – William Blair Rachel Vatnsdal – JPMorgan Sung Ji Nam – Scotiabank Operator Good day and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter 2024 Earnings Call.

Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript

Although the revenue and EPS for Adaptive Biotechnologies (ADPT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Adaptive Biotechnologies (ADPT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.33 per share a year ago.

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates

SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2024.

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

Guardant Health Inc

Illumina

Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant.

3 Precision Medicine Stocks Tailoring Treatments

SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL.

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

OPAL Fuels Inc

Talkspace

To be completely upfront, small-cap stocks to buy are risky. They're the equivalent of plus-money bets or plus odds.

Mighty Mites: 3 Small-Cap Stocks Packing a Powerful Punch

On a relatively sleepy day for the market, the biotech enjoyed a decent little price pop on earnings. Its first quarter results topped analyst estimates on both the top and bottom lines.

Why Adaptive Biotechnologies Topped the Market Today

Adaptive Biotechnologies Corporation. (NASDAQ:ADPT ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Kyle Piskel - CFO Susan Bobulsky - Senior Vice President, Diagnostics, clonoSEQ Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandberg Tom Stevens - TD Cowen Operator Good day and thank you for standing by.

Adaptive Biotechnologies Corporation (ADPT) Q1 2024 Earnings Call Transcript

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

News for Adaptive Biotechnologies Stock (ADPT)